Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7e470e09803bd6bf24b2fd176109dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff529b7e4a6c75b7dc55d7cccd348939 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2012-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0f3f47374a8ea8d390be2b20f8518eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7196b5bda70e7a67f51b21fbc09b8eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94199f0ab32be3321b57b09d681d9159 |
publicationDate |
2014-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20140104419-A |
titleOfInvention |
A method for predicting responsiveness to a treatment with an egfr inhibitor |
abstract |
The present invention relates to a method for predicting whether a cancer patient is likely to respond to an epithelial growth factor receptor (EGFR), comprising the step of measuring the expression level of hsa-miR-31-3p miRNA in a sample of a cancer patient In-house method. The invention also relates to the therapeutic use of an EGFR inhibitor in a patient expected to respond to said EGFR inhibitor. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021075662-A1 |
priorityDate |
2011-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |